These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29939507)

  • 21. Medicare Part D Protected-Class Policy Is Associated With Lower Drug Rebates.
    Kakani P; Kyle MA; Chandra A; Maini L
    Health Aff (Millwood); 2024 Oct; 43(10):1420-1427. PubMed ID: 39374459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicare Advantage coverage restrictions for the costliest physician-administered drugs.
    Anderson KE; Alexander GC; Ma C; Dy SM; Sen AP
    Am J Manag Care; 2022 Jul; 28(7):e255-e262. PubMed ID: 35852888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are Medicare plans complying with CMS regulation?
    Cohen J; Young B; Rochon S; Faden L
    Expert Rev Pharmacoecon Outcomes Res; 2008 Apr; 8(2):133-9. PubMed ID: 20528402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
    Bowman J; Rousseau A; Silk D; Harrison C
    Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should Medicare adopt the Veterans Health Administration formulary?
    Frakt AB; Pizer SD; Feldman R
    Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Narrative review: the U.S. Pharmacopeia and model guidelines for Medicare Part D formularies.
    ;
    Ann Intern Med; 2006 Sep; 145(6):448-53. PubMed ID: 16983132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients' access to 2018 FDA-approved drugs 1 year post approval.
    Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
    Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
    Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
    JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans.
    Wade RL; Chen CC; De AP; Howard JC
    J Health Econ Outcomes Res; 2017; 5(1):75-88. PubMed ID: 37664692
    [No Abstract]   [Full Text] [Related]  

  • 31. Coverage and prior authorization of psychotropic drugs under Medicare Part D.
    Huskamp HA; Stevenson DG; Donohue JM; Newhouse JP; Keating NL
    Psychiatr Serv; 2007 Mar; 58(3):308-10. PubMed ID: 17325102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do comprehensive medication review completion rates predict medication use and management quality?
    Wang Y; Farley JF; Ferreri SP; Renfro CP
    Res Social Adm Pharm; 2019 Apr; 15(4):417-424. PubMed ID: 30917893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes of ticagrelor formulary tiers in the USA: targeting private insurance providers away from government-funded plans.
    Serebruany VL; Dinicolantonio JJ
    Cardiology; 2013; 126(3):187-90. PubMed ID: 24030166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Medicare Advantage Prescription Drug Plan Star Ratings on Enrollment before and after Implementation of Quality-Related Bonus Payments in 2012.
    Li P; Doshi JA
    PLoS One; 2016; 11(5):e0154357. PubMed ID: 27149092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
    Mullins CD; Palumbo FB; Saba M
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationships between Medicare Advantage contract characteristics and quality-of-care ratings: an observational analysis of Medicare Advantage star ratings.
    Xu P; Burgess JF; Cabral H; Soria-Saucedo R; Kazis LE
    Ann Intern Med; 2015 Mar; 162(5):353-8. PubMed ID: 25732277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do Restrictions on Antipsychotic Use Differ Between Medicare Part D Stand-Alone Versus Medicare Advantage Plans?
    Chou J; Brandt NJ; Loh FE; Stuart B
    Consult Pharm; 2017 Feb; 32(2):109-118. PubMed ID: 28569663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.